These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5. Liu X; Wang H; Ma R; Shao L; Zhang W; Jiang W; Luo C; Zhai T; Xu Y Clin Exp Nephrol; 2019 Mar; 23(3):362-370. PubMed ID: 30291473 [TBL] [Abstract][Full Text] [Related]
3. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial. Kimura K; Hosoya T; Uchida S; Inaba M; Makino H; Maruyama S; Ito S; Yamamoto T; Tomino Y; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H; Ohtsu H; Ohashi Y; Am J Kidney Dis; 2018 Dec; 72(6):798-810. PubMed ID: 30177485 [TBL] [Abstract][Full Text] [Related]
4. The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study. Hosoya T; Kimura K; Itoh S; Inaba M; Uchida S; Tomino Y; Makino H; Matsuo S; Yamamoto T; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H Trials; 2014 Jan; 15():26. PubMed ID: 24433285 [TBL] [Abstract][Full Text] [Related]
5. Study of therapeutic efficacy of febuxostat in chronic kidney disease stage IIIA to stage VD. Sarvepalli PS; Fatima M; Quadri AK; Taher AR; Habeeb A; Amreen F; Parveen BN; Rajaram KG Saudi J Kidney Dis Transpl; 2018; 29(5):1050-1056. PubMed ID: 30381500 [TBL] [Abstract][Full Text] [Related]
6. Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease. Peng YL; Tain YL; Lee CT; Yang YH; Huang YB; Wen YH; Hsu CN Sci Rep; 2020 Jul; 10(1):10734. PubMed ID: 32612180 [TBL] [Abstract][Full Text] [Related]
7. Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease. Levy G; Shi JM; Cheetham TC; Rashid N Perm J; 2018; 22():17-142. PubMed ID: 30201087 [TBL] [Abstract][Full Text] [Related]
8. Effect of Febuxostat versus Allopurinol on the Glomerular Filtration Rate and Hyperuricemia in Patients with Chronic Kidney Disease. Nagaraju SP; Shenoy SV; Rao I; Prabhu RA; Rangaswamy D; Bhojaraja MV; Guddattu V Saudi J Kidney Dis Transpl; 2023 Jul; 34(4):279-287. PubMed ID: 38345582 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial. Sircar D; Chatterjee S; Waikhom R; Golay V; Raychaudhury A; Chatterjee S; Pandey R Am J Kidney Dis; 2015 Dec; 66(6):945-50. PubMed ID: 26233732 [TBL] [Abstract][Full Text] [Related]
10. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD). Sezai A; Soma M; Nakata K; Osaka S; Ishii Y; Yaoita H; Hata H; Shiono M J Cardiol; 2015 Oct; 66(4):298-303. PubMed ID: 25649025 [TBL] [Abstract][Full Text] [Related]
11. Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease. Lee JW; Lee KH Int Urol Nephrol; 2019 Mar; 51(3):467-473. PubMed ID: 30604229 [TBL] [Abstract][Full Text] [Related]
12. Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial. Tanaka A; Taguchi I; Teragawa H; Ishizaka N; Kanzaki Y; Tomiyama H; Sata M; Sezai A; Eguchi K; Kato T; Toyoda S; Ishibashi R; Kario K; Ishizu T; Ueda S; Maemura K; Higashi Y; Yamada H; Ohishi M; Yokote K; Murohara T; Oyama JI; Node K; PLoS Med; 2020 Apr; 17(4):e1003095. PubMed ID: 32320401 [TBL] [Abstract][Full Text] [Related]
13. Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study. Yang N; Cao B J Clin Pharm Ther; 2022 Dec; 47(12):2214-2222. PubMed ID: 36403976 [TBL] [Abstract][Full Text] [Related]
14. Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial). Sezai A; Unosawa S; Taoka M; Osaka S; Sekino H; Tanaka M Ann Thorac Cardiovasc Surg; 2020 Aug; 26(4):202-208. PubMed ID: 31748427 [TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study. Chou HW; Chiu HT; Tsai CW; Ting IW; Yeh HC; Huang HC; Kuo CC; Nephrol Dial Transplant; 2018 Sep; 33(9):1620-1627. PubMed ID: 29165620 [TBL] [Abstract][Full Text] [Related]
16. Febuxostat dose requirement according to renal function in patients who achieve target serum urate levels: A retrospective cohort study. Kim YE; Ahn SM; Oh JS; Kim YG; Lee CK; Yoo B; Hong S Joint Bone Spine; 2024 Mar; 91(2):105668. PubMed ID: 38036062 [TBL] [Abstract][Full Text] [Related]
18. Effects of febuxostat on delaying chronic kidney disease progression: a randomized trial in China. Yang H; Li R; Li Q; Yan T; Li Y; Huang Q; Uchida S; Chang W Int Urol Nephrol; 2023 May; 55(5):1343-1352. PubMed ID: 36534221 [TBL] [Abstract][Full Text] [Related]
19. Effect of Dotinurad on Serum Uric Acid Concentration in Chronic Kidney Disease Patients Treated with Febuxostat. Yamada T; Sakai Y; Kurihara O; Kashiwagi T; Iwabu M J Nippon Med Sch; 2024; 91(4):352-356. PubMed ID: 39231637 [TBL] [Abstract][Full Text] [Related]
20. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol. Cutolo M; Cimmino MA; Perez-Ruiz F Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]